Why the study?
Thyrotoxicosis-induced dilated cardiomyopathy is a rare but potentially life-threatening complication that can cause irreversible changes in cardiac structure and function if left untreated.
Case Report (n=1)
No
Prompt intensive treatment of thyrotoxicosis-induced cardiomyopathy with anti-thyroid and heart failure medications can rapidly reverse severe left ventricular systolic dysfunction.
Answers are grounded in this paper and cite their sources.
May support combined antithyroid and GDMT for thyrotoxic cardiomyopathy; leaves open generalizability pending controlled trials.
Thyrotoxicosis-induced dilated cardiomyopathy is a rare but potentially life-threatening complication of thyrotoxicosis, with an incidence of <1%. This condition is characterized by a dilatation of the ventricular chamber and a decrease in cardiac contractility. Untreated, it can lead to irreversible changes in cardiac structure and function, including dilated ventricular chamber, a decrease in ejection fraction (EF), and an increased risk of atrial fibrillation. We present a case of a 39-year-old patient with a diagnosis of thyrotoxicosis-induced acute heart failure. A two-dimensional (2D) echocardiogram disclosed an ejection fraction of 36%, with diffuse mild dilation of the atria and ventricles with trace mitral and tricuspid regurgitation. The anti-thyroid-stimulating hormone (TSH) receptor was positive, and Grave's disease was diagnosed. The patient eventually returned to baseline functional status and could return to basic activities of daily living without limitations. The patient was encouraged to follow up with outpatient cardiology. Early diagnosis of cardiac involvement in patients with thyrotoxicosis is critical. Promptly delivered intensive treatment with the rapid achievement of euthyroid state can potentially reverse cardiac dysfunction and improve patient outcomes.
No takes yet. Share an insight, caveat, or question.
Khalil et al. (2023) conducted a case report in Thyrotoxicosis-induced dilated cardiomyopathy (n=1). Methimazole, metoprolol, and sacubitril/valsartan was evaluated on Left ventricular ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: